go-v.orgdoi

Clinicopathological and Molecular Characterization of Non-Endometrioid Endometrial Carcinoma

Danqing Zhu, Keyi Shi, Dongxiao Hu, Wanrun Lin, Xiaofei Zhang, Feng Zhou, Yang Li · Journal of Cancer · 2025

  • DOI 10.7150/jca.108685
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2025

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2025

Abstract

Objective: Molecular classification has become an essential tool in endometrial carcinoma; however, its application in non-endometrioid carcinoma (NEEC), particularly rare histological subtypes, remains relatively unexplored.This study aims to investigate the potential utility of molecular classification in NEEC.Methods: A retrospective analysis was conducted on 167 NEEC cases diagnosed at the Women's Hospital of Zhejiang University from 2013 to 2020.The cases were categorized into four molecular subtypes: POLE ultra-mutated (POLEmut), mismatch repair-deficient (MMRd), p53-abnormal (p53abn), and no specific molecular profile (NSMP) molecular subgroups.Statistical significance was set at P<0.05.Results: Among the cases, 13 (7.8%)patients were classified as POLEmut, 25 (15.0%) as MMRd, 84 (50.3%) as p53abn, and 45 (27.0%) as NSMP.Most POLEmut cases were at early stages (11/13, 84.6% at stages I-II), whereas p53abn cases were predominantly at advanced stages (32/49, 65.3% at stages III-IV).Additionally, p53abn was the most common subtype in serous carcinoma (41/45, 91.1%) and mixed adenocarcinoma (24/57, 42.1%).The 3-year recurrence-free survival (RFS) rates for POLEmut, MMRd, NSMP, and p53abn were 100.0%,88.0%, 73.3%, and 71.4% , respectively.The 3-year overall survival (OS) rates were 100.0%,88.0%, 82.2%, and 73.8%, respectively.Univariate analysis revealed significant associations of age ≥60 years (P=0.01),hypertension (P=0.03),FIGO stage (P<0.001),lymphovascular space invasion (P=0.01),lymph node metastasis (P<0.001),myometrial invasion (P<0.001), and postoperative adjuvant therapy (P=0.01) with 3-year RFS.Multivariate analysis identified age ≥60 years (P=0.03),myometrial invasion (P=0.01), and FIGO stage (P=0.046)as independent risk factors for 3-year OS.Conclusion: Molecular classification is crucial for accurately predicting the prognosis of NEEC, enabling more tailored treatment approaches in clinical practice.Furthermore, patient age may have a significant influence on NEEC classification and progression.

Open the resolved locator · 10.7150/jca.108685

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:54 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v16p2312.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.